USANA's CEO Myron W. Wentz, Ph.D. Has Been Elected to Serve on Immunosyn Corporation's Board of...(attention to humanitarianconcerns fundin...)

Date:3/17/2008

attention to humanitarian concerns, funding the Wentz Medical Centre and Laboratory in Uganda and the Wentz Medical Center in Cambodia, both of which serve children in those countries orphaned by diseases such as malaria and HIV. He also funded construction of the Wentz Concert Hall and Fine Arts Center at his North Central College alma mater.

Dr. Wentz's business acumen has been recognized through a Presidential appointment as an advisor to the SBA and receiving an Ernst & Young Entrepreneur of the Year Award. In 2007 he received the Albert Einstein Award for lifelong achievement in science.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). (For more information on Immunosyn and SF-1019 go to http://www.immunosyn.com)

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expe
'/>"/>

SOURCE Immunosyn Corporation Copyright©2008 PR Newswire. All rights reserved

4 GOOD

Page: 1 2 3 4
Related biology technology :

1. febit Appoints Michelle Lyles, Ph.D., Vice President, Marketing and Sales
2. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
3. NeoStems Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
4. Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors
5. BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
6. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
7. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
8. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
9. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
10. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer